Day One Biopharmaceuticals, Inc. (DAWN) News

Day One Biopharmaceuticals, Inc. (DAWN): $24.88

-0.05 (-0.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DAWN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

Filter DAWN News Items

DAWN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DAWN News Highlights

  • For DAWN, its 30 day story count is now at 8.
  • Over the past 27 days, the trend for DAWN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • AGEN, ALKS and ALZN are the most mentioned tickers in articles about DAWN.

Latest DAWN News From Around the Web

Below are the latest news stories about Day One Biopharmaceuticals Inc that investors may wish to consider to help them evaluate DAWN as an investment opportunity.

Day One Appoints Jaa Roberson as Chief People Officer

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced the appointment of Jaa Roberson as chief people officer. In her role, Ms. Roberson will oversee all aspects of Day One’s human resources and talent acquisition efforts. “Day One is built on a foundation of talent

Yahoo | September 13, 2021

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) BeyondSpring Inc. (NASDAQ: BYSI ) ( moved on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate) BioLife Solutions, Inc. (NASDAQ: BLFS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) DexCom, Inc. (NASDAQ: DXCM ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Erasca, Inc. (NASDAQ: ERAS ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Imago BioSciences, Inc. (NASDAQ: IMGO ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed...

Benzinga | August 27, 2021

Insiders who bought into Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) earlier this year might wish they'd invested more as stock gained 12%

Last week, Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) insiders, who had purchased shares in the previous 12...

Yahoo | August 27, 2021

Day One Appoints Scott Garland to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the appointment of Scott Garland to the Companys board of directors. Mr. Garland is a 30-year veteran of the biopharmaceutical industry with deep commercial and executive leadership experience.

Intrado Digital Media | August 17, 2021

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck''s Keytruda On Track For More Label Expansions, Eliem Debuts

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Axonics, Inc. (NASDAQ: AXNX ) BioLife Solutions, Inc. (NASDAQ: BLFS ) (announced a deal to buy privately-held Sexton Biotech to expand cell and gene therapy tools portfolio) BioNTech SE (NASDAQ: BNTX ) (reacted to its quarterly results and raised vaccine sales forecast) Caribou Biosciences, Inc. (NASDAQ: CRBU ) (IPOed July 23) Cortexyme, Inc. (NASDAQ: CRTX ) (announced its second-quarter results) Cytokinetics, Incorporated (NASDAQ: CYTK ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Edward...

Benzinga | August 10, 2021

Day One Reports Second Quarter 2021 Financial Results and Corporate Progress

DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission Dosed the First Patients in Pivotal FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG Successfully Completed $184 Million Upsized Initial Public Offering Providing Funding into the Second Half of 2023 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing a

Yahoo | August 10, 2021

Day One Biopharmaceuticals to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that Dr. Jeremy Bender, chief executive officer, is scheduled to participate in a panel discussion at the 12th Annual Wedbush PacGrow Healthcare Conference, which is being held virtually from August 10-11, 2021. P

Yahoo | August 4, 2021

Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma

SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to the Company’s lead product candidate, DAY101, for the treatment of low-grade gliomas harboring an activating RAF a

Yahoo | July 27, 2021

JPMorgan: These 3 Stocks Could Spike at Least 70% From Current Levels

Let’s step back and take a look at the big picture, while keeping stocks in focus. Both the S&P 500 and the Nasdaq hit a series of record highs -- mainly due to increasing investor confidence that the current inflationary environment will be a transitory event rather than a sustained trend. Clearly, investors are not shy about stocks, even though the Commerce Department’s inflation indicator for May hit 3.4%, it’s fastest rate of increase since the 90s. Given this alarming disconnect, it has become more challenging to predict where the market might be heading. Economic and political forces are pulling in different directions, and the greatest certainty for now is uncertainty.

Michael Marcus on TipRanks | June 28, 2021

Day One Biopharma's experimental glioma drug gets an orphan designation in Europe

Shares of Day One Biopharmaceuticals Inc. gained 9.4% in premarket trading on Monday after the company said its experimental glioma treatment received an orphan designation in Europe. The drug candidate has already received a Breakthrough Therapy designation from U.S. regulators for one indication and an orphan designation as a treatment for malignant glioma. In the U.S., an orphan-drug designation supports developing treatments for diseases that affect fewer than 200,000 people. Gliomas are a t

Yahoo | June 21, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5808 seconds.